Phytera and Lilly to partner on infectious diseases:
This article was originally published in Clinica
Phytera and Eli Lilly are to collaborate in research to discover novel agents for the diagnosis and prevention of infectious fungal diseases. Phytera will receive an up-front equity investment, milestone payments and royalties. Lilly, based in Indianapolis, Indiana, will fund the project and have worldwide rights to commercialise any products. As part of the agreement, the Worcester, Massachusetts-based Phytera will provide its natural product chemistry for the bioassay-guided fractionation and Lilly will supply compounds for screening.